ReviewHerz2022
Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.
Hermann HallerPubMed ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it
ReviewHerz2022
Hermann HallerPubMed ↗Publisher ↗
No numbers read from the abstract.